Benitec Biopharma (BNTC) filed a registration statement Monday with the US Securities and Exchange Commission for the potential sale of up to $200 million in securities.
The filing covers common and preferred stock, debt securities, warrants and units.
Benitec shares fell 1.7% in after-hours trading.